Turnstone Biologics Corp. - Common Stock (TSBX)
Frequently Asked Questions About Turnstone Biologics Corp. - Common Stock (TSBX)
Does Turnstone engage in patient advocacy or community outreach?
Yes, Turnstone Biologics is committed to engaging in patient advocacy and community outreach. The company recognizes the importance of supporting cancer patients and their families by collaborating with advocacy groups and providing resources to raise awareness about immunotherapy advancements.
Does Turnstone have any partnerships or collaborations?
Yes, Turnstone Biologics has engaged in strategic partnerships with various organizations, including academic institutions and pharmaceutical companies. These collaborations aim to enhance its research capabilities and broaden the scope of its therapeutic programs.
How can investors find more information about Turnstone Biologics?
Investors can find more information about Turnstone Biologics through the company's official website, where they can access investor relations resources, press releases, financial reports, and updates on ongoing clinical trials and corporate developments.
How does Turnstone Biologics fund its research?
The company funds its research and development programs through a combination of equity financing from its IPO, private placements, and strategic collaborations with other biotechnology and pharmaceutical companies, as well as grants and public funding initiatives.
How does Turnstone ensure the safety of its therapies?
Turnstone Biologics places a high priority on safety by following stringent regulatory guidelines during its clinical trials. The company conducts comprehensive preclinical and clinical testing to monitor potential side effects and ensure that its therapies are safe for patient use.
How does Turnstone measure the success of its therapies?
Turnstone Biologics measures the success of its therapies through various clinical endpoints, including overall response rate, progression-free survival, and overall survival rates. These metrics help to evaluate the therapeutic effectiveness of their immunotherapy candidates.
How has Turnstone performed financially since its IPO?
Since its IPO, Turnstone Biologics has seen fluctuations in its stock price along with typical volatility associated with biotech companies. The company continues to invest in research and development, which impacts its financial performance as it seeks to translate scientific advancements into commercial success.
What are the future plans for Turnstone Biologics?
The future plans for Turnstone Biologics involve advancing its clinical pipeline, expanding its research into new therapeutic areas, and exploring partnerships that can enhance its development efforts. The company aims to bring its innovative therapies to market and improve treatment options for cancer patients.
What are the goals of Turnstone Biologics?
The primary goals of Turnstone Biologics include advancing its pipeline of innovative cancer therapies through clinical trials, enhancing the effectiveness of immunotherapies, and ultimately providing patients with safer and more effective treatment options for solid tumors.
What challenges does Turnstone face in the biotech industry?
The biotech industry presents several challenges for Turnstone Biologics, including regulatory hurdles, the need for significant financial investments, competition from other biotechnology firms, and the complexities of developing effective therapies for diverse and often resistant types of cancers.
What clinical trials is Turnstone currently conducting?
Turnstone Biologics is currently conducting several clinical trials focused on their lead candidate, TS-120. These trials are aimed at assessing the safety and efficacy of the therapy in patients with various solid tumors, including those resistant to conventional treatments.
What does Turnstone Biologics Corp. do?
Turnstone Biologics Corp. is a clinical-stage biotechnology company dedicated to developing novel immunotherapies for the treatment of cancer. The company utilizes its proprietary platform, which leverages a tumor-infiltrating lymphocyte (TIL) technology, to engineer and enhance patients' own immune cells to better target and destroy cancerous cells.
What is Turnstone's lead product candidate?
Turnstone's lead product candidate is called TS-120. This innovative therapy is designed to target solid tumors by harnessing and enhancing the body's own immune responses, specifically through engineered tumor-infiltrating lymphocytes.
What potential impacts could Turnstone's therapies have on cancer treatment?
If successful, Turnstone's therapies could significantly impact cancer treatment by providing effective options for patients with solid tumors that are currently difficult to treat, offering hope for improved outcomes and potentially increasing survival rates for these patients.
What technology does Turnstone use in its treatments?
Turnstone Biologics employs a unique approach utilizing tumor-infiltrating lymphocytes (TILs). These are immune cells that naturally occur within tumors and, when isolated and engineered, can be expanded and reinfused into patients to provide a robust anti-tumor response.
What types of cancer does Turnstone focus on?
Turnstone Biologics focuses on various types of cancer, particularly those that currently have limited treatment options. The primary focus is on solid tumors, such as melanoma and other aggressive cancers that can evade traditional therapies.
When did Turnstone Biologics go public?
Turnstone Biologics Corp. went public on September 24, 2020, when it completed its initial public offering (IPO). The company's shares began trading on the Nasdaq stock exchange under the ticker symbol TSBX.
Where is Turnstone Biologics headquartered?
Turnstone Biologics Corp. is headquartered in Ottawa, Ontario, Canada. The location serves as the central hub for its research and development activities, as well as corporate operations.
Who are the key executives at Turnstone?
Key executives at Turnstone Biologics include President and CEO Dr. Sandeep Shreeniwas, who brings extensive experience in immunotherapy, and the Chief Scientific Officer Dr. Jonathon Abraham, known for his expertise in cancer biology and immunology.
What is the current price of Turnstone Biologics Corp. - Common Stock?
The current price of Turnstone Biologics Corp. - Common Stock is 0.3527
When was Turnstone Biologics Corp. - Common Stock last traded?
The last trade of Turnstone Biologics Corp. - Common Stock was at 4:00 pm EDT on June 27th, 2025